Lord, Abbett & Co
ADMS

Lord, Abbett & Co’s Adamas Pharmaceuticals ADMS Stock Holding History

Lord, Abbett & Co’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-136,688
Closed -$3.53M – 898
2018
Q2 		$3.53M Sell
136,688
-2,623
-2% -$72.6K 0.01% 784
2018
Q1 		$3.33M Buy
+139,311
New +$4.39M 0.01% 772

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Lord, Abbett & Co's ADMS Position: Q3 2018 in Review

Lord, Abbett & Co sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 136,688 shares — an estimated $3.53M sold.

Lord, Abbett & Co first reported a position in ADMS in Q1 2018 and held it in 2 quarters. The position peaked at $3.53M in Q2 2018. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

  • Lord, Abbett & Co reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 136,688 Adamas Pharmaceuticals shares in Q3 2018, an estimated $3.53M.
  • Lord, Abbett & Co first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Lord, Abbett & Co's Adamas Pharmaceuticals position peaked at $3.53M in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on Lord, Abbett & Co's 13F filing for Q3 2018, filed 14 Nov 2018.